Wells Fargo & Company Solid Biosciences Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.51 - $7.56 $897 - $13,298	-1,759 Reduced 55.59%	1,405 $0
Q2 2022 Aug 12, 2022	SELL	$0.43 - $1.24 $3,501 - $10,098	-8,144 Reduced 72.02%	3,164 $2,000
Q1 2022 May 16, 2022	SELL	$0.74 - $1.79 $16,200 - $39,186	-21,892 Reduced 65.94%	11,308 $13,000
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.46 $14,904 - $21,694	8,819 Added 36.17%	33,200 $58,000
Q3 2021 Nov 15, 2021	SELL	$2.38 - $3.77 $111,162 - $176,085	-46,707 Reduced 65.7%	24,381 $58,000
Q2 2021 Aug 16, 2021	BUY	$3.49 - $5.51 $24,081 - $38,019	6,900 Added 10.75%	71,088 $259,000
Q1 2021 May 13, 2021	SELL	$5.37 - $10.72 $218,011 - $435,210	-40,598 Reduced 38.74%	64,188 $354,000
Q4 2020 Feb 09, 2021	BUY	$3.08 - $7.79 $182,616 - $461,876	59,291 Added 130.32%	104,786 $795,000
Q3 2020 Nov 05, 2020	SELL	$2.02 - $3.08 $110,879 - $169,064	-54,891 Reduced 54.68%	45,495 $92,000
Q2 2020 Aug 13, 2020	SELL	$2.1 - $3.42 $52,044 - $84,757	-24,783 Reduced 19.8%	100,386 $294,000
Q1 2020 May 14, 2020	BUY	$2.31 - $4.43 $289,140 - $554,498	125,169 New	125,169 $299,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $29.8M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.